Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!

List view / Grid view

Dr. Christopher Duma (Founder – Regeneration Biomedical and Medical Director of the Brain Tumor Program - Hoag Memorial Presbyterian Hospital)

 

3D illustration of damaged neurons with disrupted myelin sheaths, representing neurodegeneration in conditions such as Alzheimer’s disease.
3D illustration of damaged neurons with disrupted myelin sheaths, representing neurodegeneration in conditions such as Alzheimer’s disease.
article

Inside the Alzheimer’s study backing stem cells, not drugs

In this first-in-human Alzheimer’s study, Wnt-activated autologous stem cells are…

26 August 2025 | By

In this first-in-human Alzheimer’s study, Wnt-activated autologous stem cells are delivered intracerebroventricularly (directly into the brain) to address neuronal loss, while also reducing amyloid and tau biomarkers and improving cognition. Early data from this regenerative approach could help early drug discovery teams shape target selection, biomarker development and trial design.